DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...

Compared with DPP-4 inhibitor therapy, sustained GLP-1 receptor agonist (GLP-1 RA) therapy was associated with greater short‑ and long‑term improvements in A1c levels and a modest reduction in the ...

Type 2 diabetes already affects 230 million people and is rising at epidemic levels with a worldwide prevalence of 350 million forecast for 2025. The global population is getting progressively older ...

This study evaluates the long-term cost-effectiveness of treatment involving combination therapy with dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors ...